We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+8.24%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.42B
AUM Growth
+$102M
(+7.8%)
Cap. Flow
+$35.6M
Cap. Flow
% of AUM
2.51%
Top 10 Holdings %
Top 10 Hldgs %
72.95%
Holding
34
New
3
Increased
10
Reduced
3
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$20.5M |
| 2 |
Apogee Therapeutics
APGE
|
+$17.1M |
| 3 |
Salesforce
CRM
|
+$15.3M |
| 4 |
VALN
Valneva
VALN
|
+$15.1M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$10M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FOLD
Amicus Therapeutics
FOLD
|
+$22.4M |
| 2 |
VERV
Verve Therapeutics
VERV
|
+$13.7M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$7.34M |
| 4 |
Lexeo Therapeutics
LXEO
|
+$3.9M |
| 5 |
Kyverna Therapeutics
KYTX
|
+$3.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.34% |
| 2 | Technology | 15.92% |
| 3 | Financials | 10.18% |
| 4 | Consumer Discretionary | 2.98% |
| 5 | Industrials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
LanzaTech
LNZA
$69.8M
| $4.29M | 0.3% |
158,148
| – | – |
|
27
Marqeta
MQ
$1.66B
| $2.57M | 0.18% |
110,390
| – | – |
|
28
AbCellera Biologics
ABCL
$2.12B
| $2.24M | 0.16% |
652,529
-474,386
| -42% | -$1.18M |
|
|
DMRA
29
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
| $341K | 0.02% |
99,913
| – | – |
|
|
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-2,750,000
| Closed | -$22.4M |
|
|
31
Lexeo Therapeutics
LXEO
$378M
| – | – |
-1,122,581
| Closed | -$3.9M |
|
|
32
Rocket Pharmaceuticals
RCKT
$394M
| – | – |
-1,100,000
| Closed | -$7.34M |
|
|
VERV
33
DELISTED
Verve Therapeutics
VERV
| – | – |
-3,000,000
| Closed | -$13.7M |
|
|
34
Kyverna Therapeutics
KYTX
$484M
| – | – |
-1,850,000
| Closed | -$3.57M |
|
Similar funds
MP
FLII
IC
IA
HTHT
BCP
SPC
SC
Novo Holdings A/S's Q2 2025 Portfolio in Review
As of Q2 2025, Novo Holdings A/S held 34 positions worth $1.42B, up 7.8% from $1.31B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Novo Holdings A/S's Q2 2025 filing shows 3 new, 10 increased, 3 reduced and 5 closed positions. Its largest new stake was Enliven Therapeutics: 1,084,432 shares worth $21.8M. The largest sale was Amicus Therapeutics, an estimated $22.4M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 51% a quarter earlier, followed by Technology and Financials.
- Novo Holdings A/S's largest Q2 2025 buy was Enliven Therapeutics: 1,084,432 shares worth $21.8M.
- Novo Holdings A/S added most to Salesforce in Q2 2025, an estimated $15.3M increase.
- Novo Holdings A/S's biggest Q2 2025 reduction was Insmed, cutting an estimated $3.42M.
- Novo Holdings A/S fully exited Amicus Therapeutics in Q2 2025, selling an estimated $22.4M.
- Novo Holdings A/S's ten largest holdings make up 73% of its $1.42B portfolio in Q2 2025.
- Novo Holdings A/S opened 3 new positions and closed 5 in Q2 2025.
- Novo Holdings A/S's portfolio value rose 7.8% quarter-over-quarter to $1.42B.
Based on Novo Holdings A/S's 13F filing for Q2 2025, filed 14 Aug 2025.